ASCO 2025 | Early Phase I findings for B7-H4-directed ADC Emi-Le in solid tumors
Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, discusses initial dose escalation results from the Phase I trial (NCT05377996) of emiltatug ledadotin (Emi-Le), a B7-H4-directed dolasynthen antibody-drug conjugate (ADC), in patients with advanced solid tumors. Emi-Le was generally well tolerated, with a manageable safety profile and no unexpected toxicities. Antitumor activity was observed across dose levels, particularly in patients with high B7-H4 expression, including those previously treated with topoisomerase-1 inhibitors. These findings support continued development in B7-H4-positive triple-negative breast cancer (TNBC) and related tumor types. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
